Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0328 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD0328 | DRUG | Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel. |
| Placebo | DRUG | Administered orally as a solution once per day on day 1, and then day 3 through to day 14. |
Inclusion Criteria: * Provision of signed informed consent * Clinically normal physical findings, laboratory values, vital signs and resting ECG as judged by the investigator Exclusion Criteria: * History of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurologica...
Top 20 of 30 competitors
AZD0328 is an investigational small molecule developed by AstraZeneca PLC for Alzheimer's disease. It is a Phase 1 central nervous system candidate and has not been approved for any indication. The compound has been studied in elderly healthy volunteers rather than in patients with diagnosed Alzheimer's disease.
AZD0328 targets CHRNA7, the alpha-7 nicotinic acetylcholine receptor, and acts as an agonist at that receptor. CHRNA7 is a ligand-gated ion channel involved in cholinergic signaling in the brain, a pathway of interest in Alzheimer's disease research. Agonism at this target is the proposed mechanism of action for AZD0328.
AZD0328 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program for the compound. The drug is an internal AstraZeneca small molecule candidate rather than a partnered or licensed asset.
AZD0328 is in Phase 1 development. It is an investigational drug and has not been approved by the FDA or any other regulator. The only recorded trial is a completed Phase 1 study, and no active trials are currently listed for the compound.
AZD0328 has been evaluated in one completed Phase 1 trial, NCT00687141, titled a study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD0328 in elderly healthy subjects. That trial enrolled 112 participants in Sweden, was randomized, double blind, and placebo controlled, and included participants aged 60 years and older.